Thermo Fisher Scientific, Waltham, Mass, a world leader in serving science, and Qiagen, Venlo, the Netherlands, a leading global provider of molecular diagnostics and sample preparation technologies, today announced that their boards of directors, as well as the managing board of Qiagen, have unanimously approved Thermo Fisher’s proposal to acquire Qiagen for €39 per share in cash. The offer price represents a premium of approximately 23% to the closing price of Qiagen’s common stock on the Frankfurt Prime Standard on March 2, 2020, the last trading day prior to the announcement of the transaction. Thermo Fisher will commence a tender offer to acquire all of the ordinary shares of Qiagen.
The transaction values Qiagen at approximately $11.5 billion at current exchange rates, which includes the assumption of approximately $1.4 billion of net debt.
For further information, visit Thermo Fisher Scientific.
